injective-labs
Develops core infrastructure for the Injective blockchain ecosystem.
Company facts
- Founded
- 2018
- Employees
- 150
- Headquarters
- United States
- CEO
- Eric Chen
- Type
- Private
- Funding
- Series C · $40M · 2022
About
Injective Labs is a research and development company focused on creating unmatched Web3 infrastructure and finance solutions. As one of the core contributors to Injective, it aims to provide innovative solutions for the decentralized finance (DeFi) sector. Injective is notable for being one of the first sector-specific blockchain platforms, designed specifically for finance. It is equipped with smart contracts and is highly interoperable with prominent layer ones such as Ethereum, Solana, and Cosmos. The company is dedicated to shaping the future of finance through its advanced offering, including Helix, a decentralized order-book crypto exchange that facilitates trading in crypto assets and derivatives. Helix is lauded for its user-friendly interface and zero gas fees. Additionally, Injective Labs operates validator nodes for various promising projects within the Web3 ecosystem, ensuring the security and functionality of emerging networks. A notable product in their portfolio is Mito, a next-generation DeFi protocol that blends strategy vaults for passive yield generation with an easy-to-use token launchpad. Injective Labs stands at the forefront of the DeFi innovation, committed to fostering a free and decentralized financial landscape for all.